Rankings
▼
Calendar
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$62M
Net Income
-$62M
EPS (Diluted)
$-3.72
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$47M
Free Cash Flow
-$47M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$328M
Total Liabilities
$57M
Stockholders' Equity
$271M
Cash & Equivalents
$34M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$62M
-$50M
-22.7%
Net Income
-$62M
-$49M
-25.8%
← FY 2021
All Quarters
Q3 2021 →
MDGL Q2 2021 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena